These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 19807511)

  • 1. Severity of illness versus expected benefit in societal evaluation of healthcare interventions.
    Nord E
    Expert Rev Pharmacoecon Outcomes Res; 2001 Oct; 1(1):85-92. PubMed ID: 19807511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The societal value of universal childhood vaccination.
    Chabot I; Goetghebeur MM; Grégoire JP
    Vaccine; 2004 May; 22(15-16):1992-2005. PubMed ID: 15121312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ['Necessity' determined on the basis of disease severity when prioritising health care interventions].
    Poley MJ; Stolk EA; Brouwer WB; van Busschbach JJ
    Ned Tijdschr Geneeskd; 2002 Nov; 146(48):2312-5. PubMed ID: 12497762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caring externalities in health economic evaluation: how are they related to severity of illness?
    Jacobsson F; Carstensen J; Borgquist L
    Health Policy; 2005 Aug; 73(2):172-82. PubMed ID: 15978960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to interpret a healthcare economic analysis.
    Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health state values from multiattribute utility instruments need correction.
    Nord E
    Ann Med; 2001 Jul; 33(5):371-4. PubMed ID: 11491196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to societal problems.
    Azaroff LV
    Science; 1974 Nov; 186(4163):478. PubMed ID: 17790361
    [No Abstract]   [Full Text] [Related]  

  • 17. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.
    Garrison LP; Jackson T; Paul D; Kenston M
    J Manag Care Spec Pharm; 2019 Jul; 25(7):793-799. PubMed ID: 30784347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.
    Boujaoude MA; Mirelman AJ; Dalziel K; Carvalho N
    Cost Eff Resour Alloc; 2018; 16():18. PubMed ID: 29796012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming EQ-5D utilities for use in cost–value analysis of health programs.
    Nord E; Johansen R
    Eur J Health Econ; 2015 Apr; 16(3):313-28. PubMed ID: 24659019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity as an independent determinant of the social value of a health service.
    Richardson JR; McKie J; Peacock SJ; Iezzi A
    Eur J Health Econ; 2011 Apr; 12(2):163-74. PubMed ID: 20455072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.